Identifying CLL Patients at High Risk of Atrial Fibrillation on Treatment Using Machine Learning
Source : https://pubmed.ncbi.nlm.nih.gov/38179708/
An increased risk of developing atrial fibrillation (AF) has been observed in patients with chronic lymphocytic leukemia (CLL) who were treated with ibrutinib and other BTK inhibitors. Previous studies have...
The results demonstrated that the treatment-aware modeling, including interactions, outperformed current risk scores.
How to Improve RCHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: a Systematic Review and Meta-Analysis of 21 Randomized Controlled Trials
Source : https://pubmed.ncbi.nlm.nih.gov/38191715/
RCHOP is the standard of care for patients with diffuse large b-cell lymphoma (DLBCL) but failures occur in approximately 40% of them. We performed a meta-analysis of 21 randomized controlled...
Efficacy of RCHOP backbone is marginally improved when adding a novel antilymphoma agent.
EFNB1 Levels Determine Distinct Drug Response Patterns Guiding Precision Therapy for B-Cell Neoplasms
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10753073/
The multi-omics data has greatly improved the molecular diagnosis of B-cell neoplasms, but there is still a lack of predictive biomarkers to guide precision therapy. Here, we analyzed publicly available...
EFNB1 phosphorylation signaling network was significantly associated with the prognosis of patients with germinal center B-cell DLBCL.
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
Source : https://pubmed.ncbi.nlm.nih.gov/38072625/
Liso-cel demonstrated high CR rate and deep, durable responses with low incidence of grade ≥3 CRS, NE, and infections in patients with heavily pretreated R/R MCL, including those with high-risk,...
Lisocabtagene maraleucel resulted in rapid and durable CR with consistently high ORRs and CRs in patients with heavily pretreated R/R MCL across prespecified patient subgroups.
Primary Thyroid Lymphoma: Clinical Factors Predicting the Possibility of Diffuse Large B-Cell Lymphoma
Source : https://pubmed.ncbi.nlm.nih.gov/38078418/
Among primary thyroid lymphomas (PTLs), diffuse large B-cell lymphoma (DLBCL) has a poorer prognosis than other indolent lymphomas such as mucosa-associated lymphoid tissue (MALT) or follicular lymphoma (FL).
The survival rate of patients with DLBCL was significantly lower than that of patients with indolent lymphomas. Univariate analysis revealed a significantly higher frequency of airway stenosis in patients with DLBCL.